Related Experiment Video

Updated: Mar 6, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.8K

Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways

Hye Jung Ihn1, Ju Ang Kim1, Yong Chul Bae2

  • 1Departments of Oral Pathology and Regenerative Medicine, Kyungpook National University, Daegu 41940, Korea.

BMB Reports
|March 4, 2017
PubMed

Insights

Afatinib, a drug targeting epidermal growth factor receptor-tyrosine kinase (EGF-TK), suppresses bone-destroying osteoclast formation. This suggests afatinib may reduce bone lesions in non-small-cell lung cancer (NSCLC) metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) commonly metastasizes to bone, causing osteolytic lesions due to excessive osteoclast activity.
  • Activating mutations in epidermal growth factor receptor-tyrosine kinase (EGF-TK) are common in NSCLC.
  • Afatinib is a targeted therapy for NSCLC that irreversibly inhibits EGF-TK, but its effects on osteoclasts are unknown.

Purpose of the Study:

  • To investigate the effects of afatinib on osteoclast differentiation and activation.
  • To elucidate the underlying molecular mechanisms of afatinib's action on osteoclasts.

Main Methods:

  • Bone marrow macrophages (BMMs) were treated with receptor activator of nuclear factor κB (RANK) ligand (RANKL) to induce osteoclast formation.
  • Afatinib's impact on osteoclast differentiation, marker gene expression, and bone resorption was assessed.
  • Western blotting was used to analyze the phosphorylation of key signaling proteins, including Akt and c-Jun N-terminal kinase (JNK).

Main Results:

  • Afatinib significantly inhibited RANKL-induced osteoclast formation from BMMs.
  • Afatinib suppressed the expression of osteoclast marker genes and enhanced negative modulator gene expression.
  • Afatinib abrogated osteoclast bone resorbing activity and inhibited RANKL-mediated Akt and JNK phosphorylation.

Conclusions:

  • Afatinib effectively suppresses osteoclastogenesis by downregulating RANK signaling pathways.
  • These findings suggest afatinib has potential therapeutic benefits in reducing osteolysis associated with NSCLC bone metastasis.

More Related Videos

Stimulation of Notch Signaling in Mouse Osteoclast Precursors08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

8.4K
Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

6.4K

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.5K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.7K